http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107213254-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d94573ab2c57e8b193f3a22accddf9fe
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-537
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-481
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-808
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
filingDate 2017-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce756aa5a0dd8b11c0f5b0ce09feff28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76bea41e9cf59edebad753b914ec534f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24e4fed31e1ba01c1be16db6101d3b17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93c7a9989a2eea1d6944d390547b09bf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca2d4e6fbd360b744141442f2a87de5d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6006c4d0c75e5ede360f82ddb3ccb288
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fa874f04583fb19d60f144369e9db5d
publicationDate 2017-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-107213254-A
titleOfInvention Purposes of the Compound Xueshuantong preparation in the treatment disease mediated medicines of PAF are prepared
abstract Present invention firstly discloses purposes of the Compound Xueshuantong preparation in the disease medicament for preparing treatment PAF mediations.The rat acute qi depression to blood stasis model experiment that the present invention is induced by using ice-water bath joint injection adrenaline is proved, Compound Xueshuantong preparation can significantly inhibit platelet activating factor (PAF) activity, have significant curative effect to the relevant disease for the treatment of PAF mediations.The treatment of the diseases such as the myocarditis, asthma, pulmonary emphysema, acute pancreatitis or the gastroenteritic ulcer that are particularly mediated by PAF.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022027898-A1
priorityDate 2017-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID44681
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCAAA60108
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID38868
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID838
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID518283
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID5724
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100720710
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID38868
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID44681
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24906312
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID447683085
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425165935
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457766107

Total number of triples: 40.